Market Place
Sourcing Support
Valneva & LimmaTech Begin Phase 2b Shigella Vaccine Study
13 Nov 2024 //
GLOBENEWSWIRE
Valneva And LimmaTech Awarded FDA Fast Track For Tetravalent Shigella
16 Oct 2024 //
GLOBENEWSWIRE
Valneva Pays LimmaTech $10M For Shigella Vaccine
02 Aug 2024 //
FIERCE BIOTECH
Valneva And LimmaTech Partner On Shigella Vaccine Development
01 Aug 2024 //
GLOBENEWSWIRE
LimmaTech Appoints Staph Leavenworth Bakali as Chairman of the Board
01 Jul 2024 //
BUSINESSWIRE
LimmaTech Reports Positive Interim Phase I/II Clinical Data on Vaccine S4V
22 Feb 2024 //
BUSINESSWIRE
LimmaTech Biologics Adds Additional $3 Million in Series A Second Closing
01 Feb 2024 //
BUSINESSWIRE
LimmaTech Biologics Expands Vaccine Pipeline
19 Dec 2023 //
BUSINESSWIRE
LimmaTech Biologics Raises $37 Million Series A
09 Oct 2023 //
BUSINESSWIRE
LimmaTech regains Shigella shot from GSK, new CEO from CureVac
20 Jul 2023 //
FIERCE BIOTECH
LimmaTech Enters License and Collaboration Agreement with Griffith University
24 Oct 2022 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.